The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 20, Issue 1, 2017, Pages 85-92

  Porres, D ^a   Pfister, D ^a   Thissen, A ^a   Kuru, T H ^a   Zugor, V ^a   Buettner, R ^a   Knuechel, R ^b   Verburg, F A ^b,c   Heidenreich, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DERIVATIVE; FLUORETHYLCHOLINE F 18; FLUORINE 18; GALLIUM 68; PROSTATE SPECIFIC ANTIGEN; TRACER; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PEROPERATIVE COMPLICATION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; VERY ELDERLY; CANCER GRADING; CANCER STAGING; MIDDLE AGED; MORTALITY; PROCEDURES; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84994680434     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2016.54     Document Type: Article

References (49)

1. Heidenreich A, Bastian P, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part I: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-137.
2. Briganti A, Karnes J, Da Pozzo L, Cozzarini C, Gallina A, Suardi N et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009; 55: 261-270.
3. Schiavina R, Manferrari F, Garofalo M, Bertaccini A, Vagnoni V, Guidi M et al. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate-And high-risk prostate cancer. BJU Int 2011; 108: 1262-1268.
4. Moschini M, Fossati N, Abdollah F, Gandaglia G, Cucchiara V, Dell'Oglio P et al. Determinants of long-Term survival of patients with locally advanced prostate cancer: The role of extensive pelvic lymph node dissection. Prostate Cancer Prostatic Dis 2016; 19: 63-67.
5. Bill-Axelson A, Holmberg L, Garmo H, Rider J, Taari K, Busch C et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932-942.
6. Mullins J, Feng Z, Trock B, Epstein J, Walsh P, Loeb S. The Impact of anatomical radical retropubic prostatectomy on cancer control: The 30-year anniversary. J Urol 2012; 188: 2219-2224.
7. Boorjian S, Thompson R, Tollefson M, Rangel L, Bergstralh E, Blute M et al. Long-Term risk of clinical progression after biochemical recurrence following radical prostatectomy: The impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-899.
8. Suardi N, Porter C, Reuther A, Walz J, Kodama K, Gibbons R et al. A nomogram predicting long-Term biochemical recurrence after radical prostatectomy. Cancer 2008; 112: 1254-1263.
9. Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
10. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-479.
11. Palmbos P, Hussain M. Non-castrate metastatic prostate cancer: have the treatment options changed? Semin Oncol 2013; 40: 337-346.
12. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature. Eur Urol 2015; 67: 852-863.
13. Pond G, Sonpavde G, de Wit R, Eisenberer M, Tannock I, Armstrong A. The prognostic importance of metastatic site in men with metastatic castrationresistant prostate cancer. Eur Urol 2014; 65: 3-6.
14. Yossepowitch O, Bianco F Jr, Eggener S, Eastham J, Scher H, Scardino P. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007; 51: 940-948.
15. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D et al. Long-Term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2015; 67: 299-309.
16. Weichselbaum R, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8: 378-382.
17. Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level o0.5 ng/ml. Clin Nucl Med 2013; 38: 342-345.
18. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185-1190.
19. Eder M, Schäfer M, Bauder-Wöst U, Hull W-E, Wängler C, Mier W et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem 2012; 23: 688-697.
20. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate 2015; 75: 1934-1940.
21. Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 2016; 43: 1410-1417.
22. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-1686.
23. Albers P, Foster RS, Voges GE, Donohue JP. Nervsparing retroperitoneal lymphadenectomy. In: Albers P, Heidenreich A (eds). Standard Operations in Urology, 2nd edn. Georg Thieme Verlag KG: Stuttgart, Germany, 2014, pp 334-342.
24. Dindo D, Demartines N, Clavien P. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
25. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011; 60: 935-943.
26. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012; 188: 2190-2197.
27. Tilki D, Mandel P, Seeliger F, Kretschmer A, Karl A, Ergun S et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol 2015; 193: 484-490.
28. Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 2015; 67: 839-849.
29. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 2015; 193: 111-116.
30. Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008; 81: 191-197.
31. Winter A, Henke RP, Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-Term follow-up. BMC Urol 2015; 15: 10.
32. de Jong I, Pruim J, Elsinga P, Vaalburg W, Mensink H. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44: 32-38.
33. Afshar-Oromieh A, Avtzi E, Giesel F, Holland-Letz T, Linhart H, Eder M et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
34. Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43: 397-403.
35. Afshar-Oromieh A, Zechmann C, Malcher A, Eder M, Eisenhut M, Linhart H et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20.
36. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014; 65: 1034-1043.
37. Abdollah F, Karnes R, Suardi N, Cozzarini C, Gandaglia G, Fossati N et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 2014; 32: 3939-3947.
38. Touijer K, Mazzola C, Sjoberg D, Scardino P, Eastham J. Long-Term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 2014; 65: 20-25.
39. Nguyen P, Alibhai S, Basaria S, D'Amico A, Kantoff P, Keating N et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67: 825-836.
40. Keating N, O'Malley A, Freedland S, Smith M. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 2013; 64: 159-166.
41. Karantanos T, Corn P, Thompson T. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013; 32: 5501-5511.
42. Tree A, Khoo V, Eeles R, Ahmed M, Dearnaley D, Hawkins M et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14: 28-37.
43. Martini T, Mayr R, Trenti E, Palermo S, Comploj E, Pycha A et al. The role of C-choline-PET/CT-guided secondary lymphadenectomy in patients with PSA failure after radical prostatectomy: lessons learned from eight cases. Adv Urol 2012; 2012: 1-4.
44. Schilling D, Schlemmer H, Wagner P, Böttcher P, Merseburger A, Aschoff P et al. Histological verification of 11C-choline-positron emission/computed tomographypositive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008; 102: 446-451.
45. Winter A, Uphoff J, Henke R, Wawroschek F. First results of [11C]choline PET/CTguided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010; 84: 418-423.
46. Wolff I, Grimm M, Wirth M. Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent. Urol A 2008; 47: 1436-1440.
47. Zattoni F, Nehra A, Murphy C, Rangel L, Mynderse L, Lowe V et al. Mid-Term outcomes following salvage lymph node dissection for prostate cancer recurrence status post-radical prostatectomy. Eur Urol Focus 2016. (available at http://dx.doi.org/10.1016/j.euf.2016.01.008).
48. Stenzl A. Salvage lymph node dissection in recurrent prostate cancer patients. Eur Urol 2011; 60: 944-945.
49. Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A et al. Prostatespecific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol 2015; 68: 530-534.